drugset

drugset / Trial / NCT06704009

NT-101 Topical Ophthalmic Solution in Patients With Wet AMD

NCT06704009 ↗

Phase 1/2 Completed 20 enrolled NexThera Co., Ltd. KCRN Research, LLC · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)

Timeline

Start: 2025-03-11
Primary completion: 2025-12-15
Completion: 2026-05-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NT-101	Unknown	—	Topical

Indications